Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Fang R, Hu H, Zhou Y, Wang S, Mei Z, She R, Peng X, Jiang Q, Wang X, Xie L, Lin H, Meng P, Zhang K, Wang W, Xie Y, Liu L, Tong J, Wu D, Luo Y, Liu C, Lu Y, Yu S, Cheng S, Xu L, Fang Z, Shang H, Ge J

Open source

DOI: 10.3389/fphar.2022.967457
Published: 2022
Container: Frontiers in pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2022.967457,
  title = {Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial.},
  author = {Fang R and Hu H and Zhou Y and Wang S and Mei Z and She R and Peng X and Jiang Q and Wang X and Xie L and Lin H and Meng P and Zhang K and Wang W and Xie Y and Liu L and Tong J and Wu D and Luo Y and Liu C and Lu Y and Yu S and Cheng S and Xu L and Fang Z and Shang H and Ge J},
  year = {2022},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2022.967457},
  url = {https://doi.org/10.3389/fphar.2022.967457}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial.
AU  - Fang R
AU  - Hu H
AU  - Zhou Y
AU  - Wang S
AU  - Mei Z
AU  - She R
AU  - Peng X
AU  - Jiang Q
AU  - Wang X
AU  - Xie L
AU  - Lin H
AU  - Meng P
AU  - Zhang K
AU  - Wang W
AU  - Xie Y
AU  - Liu L
AU  - Tong J
AU  - Wu D
AU  - Luo Y
AU  - Liu C
AU  - Lu Y
AU  - Yu S
AU  - Cheng S
AU  - Xu L
AU  - Fang Z
AU  - Shang H
AU  - Ge J
PY  - 2022
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2022.967457
UR  - https://doi.org/10.3389/fphar.2022.967457
ER  -

APA

R, F., H, H., Y, Z., S, W., Z, M., R, S., X, P., Q, J., X, W., L, X., H, L., P, M., K, Z., W, W., Y, X., L, L., J, T., D, W., Y, L., C, L., Y, L., S, Y., S, C., L, X., Z, F., H, S., & J, G. (2022). Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2022.967457

Source records

pubmed · retrieved 2026-09-25T00:40:08.884Z